Urolog. pro Praxi, 2008; 9(5): 236-241

Contemporary view to overactive bladder and treatment strategy in male patients

MUDr. Radovan Vrtal Ph.D, MUDr. Aleš Vidlář, MUDr. Michal Grepl, et al
Urologická klinika FN a LF UP v Olomouci

Overactive bladder is a chronical dissease of lower urinary tract. This express oneself through the complex of symptoms wich are very bothersome and limited from the point of view patiens QOL. International Continence Society (ICS) changed many times definition of OAB. The last one characterized OAB by urinary urgency, with or without urinary incontinence, usually with frequency and nocturia. In the course of the last years it is evident close correlation between LUTS and OAB symptoms in men patiens.

Keywords: overactive bladder, BHP, diagnostics, treatment

Published: December 20, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vrtal R, Vidlář A, Grepl M, al E. Contemporary view to overactive bladder and treatment strategy in male patients. Urol. praxi. 2008;9(5):236-241.
Download citation

References

  1. Blaivas J, Chancellor MB, Kay GG. Thinking Beoynd Urgency and Frequency, Expert Opinions in Urology, Annenberg Center for Health Science, Project 4617/2008.
  2. Brading A. A myogenic basis for the overactivity bladder. Urology 1997; 50: 57-67. Go to original source... Go to PubMed...
  3. Hu TW, Wagner TH, Benkover JD, et al. Estimated economic costs of overactive bladder in the United States. Urology 2003; 61: 1123-1128. Go to original source... Go to PubMed...
  4. Chapple C, Khullar V, Gabriel Z, Dooley JA. The effects of antimuskarinic treatments in overactive bladder: A systematic review and meta-analysis. Eur. Urol. 2005; 48: 5-26. Go to original source... Go to PubMed...
  5. Chapple C, Roehrborn CG. A Shifted Paradigm for the Further Understanding, Evaluation and Tretment of Lower Urinary Tract Symptoms in Men: Focus on the Bladder. Eur. Urol 2006; 49: 651-659. Go to original source... Go to PubMed...
  6. Irwin DF, Milsom I, Kopp Z, et al. Impact of overactive bladder symptoms on employment, social interactions and emotional wellbeing in six European countries. BJU Int. 2006; 97: 96-100. Go to original source... Go to PubMed...
  7. Jumadilova Z, Harris H, del Aguila M, Wagner S, Boccuzzi S, Bavendan T. Agent selection for overactive bladder patiens with and without commorbid benign prostatic hyperplasia (Abstrakt 486, ICS 2005).
  8. Kaplan SA, Walmsey K. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 2005; 174: 2273-2276. Go to original source... Go to PubMed...
  9. Lee JY, Kim WH, Lee SJ, Suh HJ, Chancellor MB. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder otlet obstruction and an overactive bladder. BJU int. 2004; 94: 817-820. Go to original source... Go to PubMed...
  10. Mostin JL. Patophysiology: the varieties of bladder overactivity. Urology 2002; 60: 22-26. Go to original source... Go to PubMed...
  11. Oyama IA, Rejba A, Lukban JC, FlatcherE, Kellogg-Spadt, Holzberg AS, Whitmore KE. Modified Thiele massage as therapeutic intervention for female patients with interstitial cystitis and high-tone pelvic floor dysfunction. Urology 2004; 64(5): 862-865. Go to original source... Go to PubMed...
  12. Roehrborn CG, Guan Z, Wang JT, Rovnej ES, KaplanSA. Efficacy and safety of tolterodine in male patiens with overactive bladder and urinary incontinence. Presented at: Society for Urodynamics and Female Urology, 2005, Orlando, FL.
  13. Romanzi LJ, Groutz A, Hertz DM, Blaivas JG. Involuntary detruzor contractions:correlation of urodynamic data to clinical categories. Neurourol. Urodyn 2001; 20: 249-257. Go to original source... Go to PubMed...
  14. Weiss JM a kol. Pelvic floor myofascial trigger points: manual therapy for interstitial cystitis and the urgency-frequency syndrome. J Urol. 2001; 166(6): 2226-2231. Go to original source... Go to PubMed...




Urology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.